(Q40218014)

18 September 2017

title

PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma (English)

1 reference

18 September 2017

0 references

5

Hitoshi Tsuda

1 reference

18 September 2017

Ken-ichi Kozaki

1

1 reference

18 September 2017

Issei Imoto

2

1 reference

18 September 2017

Atiphan Pimkhaokham

3

1 reference

18 September 2017

Shogo Hasegawa

4

1 reference

18 September 2017

Ken Omura

6

1 reference

18 September 2017

Johji Inazawa

7

1 reference

18 September 2017

publication date

1 December 2006

1 reference

18 September 2017

1 reference

18 September 2017

volume

97

1 reference

18 September 2017

issue

12

1 reference

18 September 2017

page(s)

1351-1358

1 reference

describes a project that uses

18 September 2017

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00343.X

Cancer genes and the pathways they control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00343.X

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00343.X

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00343.X

Oncogenic PI3K deregulates transcription and translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00343.X

Functional analysis of PIK3CA gene mutations in human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00343.X

Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00343.X

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00343.X

Mutant PIK3CA promotes cell growth and invasion of human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00343.X

Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00343.X

Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00343.X

DNA copy number gains in head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00343.X

PIK3CA mutations in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00343.X

SNO is a probable target for gene amplification at 3q26 in squamous-cell carcinomas of the esophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00343.X

Frequent silencing of low density lipoprotein receptor-related protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in esophageal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00343.X

Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00343.X

Mutations of PIK3CA in gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00343.X

PIK3CA mutations in advanced ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00343.X

PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00343.X

PIK3CA is implicated as an oncogene in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00343.X

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00343.X

Cancer drugs. Smart weapons prove tough to design

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00343.X

Targeting targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00343.X

The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00343.X

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00343.X

Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00343.X

Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00343.X

10.1111/J.1349-7006.2006.00343.X

21 January 2018

Identifiers

DOI

1 reference

18 September 2017

1 reference